Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 + Sunitinib in Advanced/Metastatic RCC
NCT01265901Phase 3Completed
- Sponsor
- Immatics
- Start
- Dec 2010
- Primary completion
- Jul 2015
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 11
01
Overview
A Phase 3 trial of IMA901 in renal cell carcinoma (RCC), sponsored by Immatics. Started Dec 2010; status: completed.
02
Drugs
IMA901
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01265901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265901.